Breaking Down SG&A Expenses: Biogen Inc. vs Novavax, Inc.

A Tale of Two Biotech Giants: Biogen Inc. vs Novavax, Inc.

In the ever-evolving biotech industry, understanding the financial dynamics of leading companies is crucial. Biogen Inc. and Novavax, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Biogen's SG&A expenses have consistently been around 90% higher than Novavax's, reflecting its established market presence and extensive operational scale. Notably, Biogen's expenses peaked in 2021, marking a 38% increase from 2014, while Novavax saw a dramatic rise in 2022, with expenses surging by over 2,300% since 2014. This stark contrast highlights Biogen's steady growth and Novavax's rapid expansion, particularly during the COVID-19 pandemic. As the biotech landscape continues to shift, these financial insights offer a glimpse into the strategic priorities and market positioning of these two industry leaders.